Sabrina Battista

Dr. Sabrina Battista

Istituto per l’Endocrinologia e l’Oncologia Sperimentale “G. Salvatore” (IEOS), CNR, Naples, Italy
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2006 in Cancer Cell
Verified
Journal Article
Closed access
Monica FedeleMonica Fedele
Monica Fedele
Rosa VisoneRosa Visone
Rosa Visone
IMIvana De Martino
Ivana De Martino
GTGiancarlo Troncone
Giancarlo Troncone
DPDario Palmieri
Dario Palmieri
Alfredo FuscoAlfredo Fusco
Alfredo Fusco

1 November 2005 in Biomaterials
Verified
Journal Article
Closed access
SBSabrina Battista
Sabrina Battista
DGDaniela Guarnieri
Daniela Guarnieri
CBCristina Borselli
Cristina Borselli
SZStefania Zeppetelli
Stefania Zeppetelli
ABAssunta Borzacchiello
Assunta Borzacchiello
PNPaolo Netti
Paolo Netti

7 May 2002 in Oncogene
Verified
Journal Article
Closed access
PDF file
Monica FedeleMonica Fedele
Monica Fedele
SBSabrina Battista
Sabrina Battista
LKLawrence Kenyon
Lawrence Kenyon
Gustavo BaldassarreGustavo Baldassarre
Gustavo Baldassarre
VFVincenzo Fidanza
Vincenzo Fidanza
Alfredo FuscoAlfredo Fusco
Alfredo Fusco

Verified
Journal Article
Open access
PDF file
Monica FedeleMonica Fedele
Monica Fedele
RSRiccardo Sgarra
Riccardo Sgarra
SBSabrina Battista
Sabrina Battista
Laura CerchiaLaura Cerchia
Laura Cerchia
Guidalberto ManfiolettiGuidalberto Manfioletti
Guidalberto Manfioletti
The transition between epithelial and mesenchymal phenotype is emerging as a key determinant of tumor cell invasion and metastasis. It is a plastic process in which epithelial cells first acquire the ability to invade the extracellular matrix and migrate into the bloodstream via transdifferentiation into mesenchymal cells, a phenomenon known as epithelial–mesenchymal transition (EMT), and then reacquire the epithelial phenotype, the reverse process called mesenchymal–epithelial transition (MET), to colonize a new organ. During all metastatic stages, metabolic changes, which give cancer cells the ability to adapt to increased energy demand and to withstand a hostile new environment, are also important determinants of successful cancer progression. In this review, we describe the complex interaction between EMT and metabolism during tumor progression. First, we outline the main connections between the two processes, with particular emphasis on the role of cancer stem cells and LncRNAs. Then, we focus on some specific cancers, such as breast, lung, and thyroid cancer.

16 October 1997 in Oncogene
Verified
Journal Article
Closed access
Roberta ViscontiRoberta Visconti
Roberta Visconti
JCJanete Cerutti
Janete Cerutti
SBSabrina Battista
Sabrina Battista
Monica FedeleMonica Fedele
Monica Fedele
FTFrancesco Trapasso
Francesco Trapasso
AFAlfredo Fusco
Alfredo Fusco

28 February 2005 in Oncogene
Verified
Journal Article
Open access
PDF file
Monica FedeleMonica Fedele
Monica Fedele
Francesca PentimalliFrancesca Pentimalli
Francesca Pentimalli
Gustavo BaldassarreGustavo Baldassarre
Gustavo Baldassarre
SBSabrina Battista
Sabrina Battista
AKAndres Jp Klein-Szanto
Andres Jp Klein-Szanto
Alfredo FuscoAlfredo Fusco
Alfredo Fusco
Overexpression of HMGA1 proteins is a constant feature of human carcinomas. Moreover, rearrangements of this gene have been detected in several human benign tumors of mesenchymal origin. To define the role of these proteins in cell transformation in vivo, we have generated transgenic mice overexpressing ubiquitously the HMGA1 gene. These mice developed mixed growth hormone/prolactin cell pituitary adenomas and natural killer (NK)-T/NK cell lymphomas. The HMGA1-induced expression of IL-2 and IL-15 proteins and their receptors may account for the onset of these lymphomas. At odds with mice overexpressing a wild-type or a truncated HMGA2 protein, adrenal medullar hyperplasia and pancreatic islet cell hyperplasia frequently occurred and no increase in body size and weight was observed in HMGA1 mice. Taken together, these data indicate an oncogenic role of the HMGA1 gene also in vivo.